The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Intersection · Pharmacology × semaglutide

Pharmacology topics tagged semaglutide

Topics in Pharmacology carrying the tag semaglutide. GLP-1 receptor agonist; the compound with the largest published human dataset in this class.

29 topics

TopicParticipantsRepliesViewsActivity
Receptor desensitisation as a tolerance hypothesis, and its weak evidence
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — setting out what I have, and where I think it stops being reliable. A documentation question rather than an analytical one. I have a…
MAVSOVSKMP+52 57 25k just now
GLP-1 receptor distribution: central and peripheral
Posting this under the heading it deserves: GLP-1 receptor distribution: central and peripheral Everything below is what sits behind that. A documentation question rather than an analytical one. I have a…
KHBPJNNSNH+90 98 30k 22h
Peak-to-trough ratio at steady state for a weekly agent — the long version
Peak-to-trough ratio at steady state for a weekly agent — the long version Writing it up because I had to work it out twice and would rather nobody else did. I would like to understand what this number means…
CTRSWAVUC+57 61 708 1d
Coming back to: Time to steady state after a dose increase
Time to steady state after a dose increase Writing it up because I had to work it out twice and would rather nobody else did. Posting the method first, because I know what the first three replies will…
MSPMAICLAP+104 110 16k 2d
About the Receptor biology category
GLP-1, GIP, glucagon and amylin receptor signalling, bias, desensitisation and central versus peripheral action. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit…
OBDOSOIKP+6 10 34k 20d
Peak-to-trough ratio at steady state for a weekly agent
On the subject in the title: Peak-to-trough ratio at steady state for a weekly agent Working notes rather than a conclusion. I would like to understand what this number means before I repeat it anywhere. A…
SMVNICPAJH+58 64 9.7k 2mo
Clearance pathways and what renal impairment changes
Clearance pathways and what renal impairment changes Writing it up because I had to work it out twice and would rather nobody else did. I would like to understand what this number means before I repeat it…
BAWADAKLS+11 15 43k 2mo
Coming back to: Washout: how long is long enough, and for what purpose
Posting this under the heading it deserves: Washout: how long is long enough, and for what purpose Everything below is what sits behind that. Working through the identity arithmetic and I would like it…
AWBWCEAWS+128 139 3k 3mo
GLP-1 receptor distribution: central and peripheral — one year on
GLP-1 receptor distribution: central and peripheral — one year on — setting out what I have, and where I think it stops being reliable. A documentation question rather than an analytical one. I have a…
GRECSVTTTV+7 11 43k 3mo
Coming back to: Half-life, steady state, and accumulation worked through
On the subject in the title: Half-life, steady state, and accumulation worked through Working notes rather than a conclusion. Working through the identity arithmetic and I would like it checked. semaglutide…
CRHKASMISC+14 18 15k 3mo
Half-life, steady state, and accumulation worked through — a second dataset
Half-life, steady state, and accumulation worked through — a second dataset — setting out what I have, and where I think it stops being reliable. Working through the identity arithmetic and I would like it…
EDRFCHLIAK+110 126 14k 4mo
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long version
Posting this under the heading it deserves: Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long version Everything below is what sits behind that. I would like to understand…
LRAAEVDMA+57 63 1k 6mo
Follow-up: Glucagon receptor agonism in a weight-loss compound
Glucagon receptor agonism in a weight-loss compound Writing it up because I had to work it out twice and would rather nobody else did. I would like to understand what this number means before I repeat it…
AMHNDNLAMD+5 9 21k 7mo
About the Pharmacokinetics category
Half-life, accumulation, steady state, albumin binding, and why weekly dosing works. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…
KTVSMNARF 4 32k 8mo
Follow-up: Why appetite effects are mostly central
Asking directly, because I could not find a straight answer: Why appetite effects are mostly central A documentation question rather than an analytical one. I have a certificate in front of me that reports a…
CRRWMHKMN+86 90 61k 9mo
Amylin receptor signalling and satiety
Amylin receptor signalling and satiety Writing it up because I had to work it out twice and would rather nobody else did. A documentation question rather than an analytical one. I have a certificate in front…
SGBCTNNATT+22 26 1.8k 9mo
Follow-up: Subcutaneous absorption kinetics and site differences
Subcutaneous absorption kinetics and site differences — setting out what I have, and where I think it stops being reliable. I would like to understand what this number means before I repeat it anywhere. A…
HCFPNVBICM 4 9.9k 10mo
Washout: how long is long enough, and for what purpose
Washout: how long is long enough, and for what purpose — setting out what I have, and where I think it stops being reliable. A documentation question rather than an analytical one. I have a certificate in…
BBNKPABRE+63 70 13k 10mo
GIP receptor agonism and the argument about direction
GIP receptor agonism and the argument about direction — setting out what I have, and where I think it stops being reliable. Posting the method first, because I know what the first three replies will otherwise…
ACQZES 2 867 10mo
Vagal afferents and the gut-brain pathway — one year on
Vagal afferents and the gut-brain pathway — one year on Writing it up because I had to work it out twice and would rather nobody else did. A documentation question rather than an analytical one. I have a…
AKTLAW 2 136 11mo
Subcutaneous absorption kinetics and site differences
Posting this under the heading it deserves: Subcutaneous absorption kinetics and site differences Everything below is what sits behind that. I would like to understand what this number means before I repeat…
NRVRMRNSS+15 19 3.9k 12mo
Vagal afferents and the gut-brain pathway
On the subject in the title: Vagal afferents and the gut-brain pathway Working notes rather than a conclusion. A documentation question rather than an analytical one. I have a certificate in front of me that…
KRBSKSBCD+5 9 44k 13mo
Half-life, steady state, and accumulation worked through
Half-life, steady state, and accumulation worked through Writing it up because I had to work it out twice and would rather nobody else did. Working through the identity arithmetic and I would like it checked.…
OVJSRPTS+115 130 44k 13mo
Albumin binding and how it produces a long half-life
Albumin binding and how it produces a long half-life — setting out what I have, and where I think it stops being reliable. I would like to understand what this number means before I repeat it anywhere. A…
SDDMTBBTAM+38 44 6.6k 14mo
Why appetite effects are mostly central
Why appetite effects are mostly central I have a specific reason for asking rather than idle curiosity, and the context is below. Posting the method first, because I know what the first three replies will…
EKHFSB 2 56k 16mo
Biased agonism: a real phenomenon, an over-used explanation
Posting this under the heading it deserves: Biased agonism: a real phenomenon, an over-used explanation Everything below is what sits behind that. A documentation question rather than an analytical one. I…
HASLFRGTSL+130 135 23k 16mo
Second pass at: Albumin binding and how it produces a long half-life
Posting this under the heading it deserves: Second pass at: Albumin binding and how it produces a long half-life Everything below is what sits behind that. I would like to understand what this number means…
BRIJVPYR+7 11 31k 17mo
Glucagon receptor agonism in a weight-loss compound
On the subject in the title: Glucagon receptor agonism in a weight-loss compound Working notes rather than a conclusion. Posting the method first, because I know what the first three replies will otherwise…
OBLMJM 2 5.1k 20mo
Time to steady state after a dose increase
On the subject in the title: Time to steady state after a dose increase Working notes rather than a conclusion. A documentation question rather than an analytical one. I have a certificate in front of me that…
LCKJSLKC+151 163 9.7k 21mo